Anales de la RANM

167 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LA TOXICIDAD CARDIOVASCULAR DE LOS FÁRMACOS ANTICANCEROSOS Tamargo J An RANM. 2023;140(02):153 - 168 and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022; 23: e333-e465. 6. Tamargo J, Caballero R, Delpón E. Cardiovas- cular drugs-from A to Z, Chapter 8.1. En: Kaski Juan Carlos and Kjeldsen Keld Per. The ESC hand- book on cardiovascular pharmacotherapy. 2nd ed. Oxford: Oxford University Press; 2019. p. 413-812. 7. Beavers CJ, Rodgers JE, Bagnola AJ et al. Car- dio-oncology drug interactions: a scientific statement from the American Heart Associa- tion. Circulation. 2022; 145: e811-e838. 8. Hassen LJ, Lenihan DJ, Baliga RR. Hyperten- sion in the cardio-oncology clinic. Heart Fail Clin. 2019; 15: 487-495. 9. Touyz RM, Herrmann SMS, Herrmann J. Vas- cular toxicities with VEGF inhibitor therapies- focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018; 12: 409-425. 10. Cohen JB, Brown NJ, Brown SA et al. Can- cer therapy-related hypertension: a scientific statement from the American Heart Associa- tion. Hypertension. 2023; 80: e46-e57. 11. Tamargo J, Caballero R, Delpón E. Cancer che- motherapy and cardiac arrhythmias: a review. Drug Saf. 2015; 38: 129-152. 12. Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: Focus on che- motherapy and targeted therapies. Circ Arr- hythmia Electrophysiol. 2017; 10: e005443. 13. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: Atrial fibrillation in can- cer. J Am Coll Cardiol. 2014; 63: 945-953. 14. Yun JP, Choi EK, Do Han K et al. Risk of atrial fibrillation according to cancer type: a nation- wide population-based study. JACC CardioOn- cology. 2021; 3: 221-232. 15. Guha A, Fradley MG, Dent SF et al. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Eur Heart J. 2021; 43: 300-312. 16. Hu YF, Liu CJ, Chang PMH et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer pa- tients. Int J Cardiol. 2013; 165: 355-357. 17. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of ar- terial hypertension. Eur Heart J. 2018; 39: 3021- 3104. 18. Potter AS, Patel A, Khawaja M et al. Outcomes by class of anticoagulant use for nonvalvular atrial fibrillation in patients with active can- cer. JACC CardioOncol. 2022; 4(3): 341-350. 19. Farge D, Frere C, Connors JM et al. 2022 in- ternational clinical practice guidelines for the treatment and prophylaxis of venous throm- boembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022; 23(7): e334-e347. 20. European Medicines Agency. ICH guideli- ne E14/S7B on clinical and nonclinical eva- luation of QT/QTc interval prolongation and proarrhythmic potential: questions and answers. Sci Med Heal 2020: EMA/CHMP/ ICH/415588/2020. 21. Tisdale JE, Chung MK, Campbell KB et al. Drug-induced arrhythmias: a scientific state- ment from the American Heart Association. Circulation. 2020; 142: E214-E233. 22. Fradley MG, Beckie TM, Brown SA et al. Recogni- tion, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart As- sociation. Circulation. 2021; 144: E41-E55. 23. Zeppenfeld K, Tfelt-Hansen J, de Riva M et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43: 3997-4126. 24. Suter TM, Ewer MS. Cancer drugs and the heart: Importance and management. Eur Heart J. 2013; 34: 1102-1111. 25. Riccio G, Coppola C, Piscopo G et al. Trastuzu- mab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? Hum Vaccin Immunother. 2016; 12(5): 1124-1131. 26. Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hor- tobagyi GN, Blum RH. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer. 2015; 51: 2314-2320. 27. Gulati G, Heck SL, Ree AH et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, ran- domized, placebo-controlled, double-blind cli- nical trial of candesartan and metoprolol. Eur Heart J. 2016; 37: 1671-1680. 28. Gulati G, Heck SL, Røsjø H et al. Neurohor- monal blockade and circulating cardiovascu- lar biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) study. J Am Heart Assoc. 2017; 6: e006513. 29. Pituskin E, Mackey JR, Koshman S et al. Mul- tidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the preven- tion of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017; 35: 870-877. 30. Boekhout AH, Gietema JA, Kerklaan BM et al. Angiotensin II receptor inhibition with can- desartan to prevent trastuzumab-related car- diotoxic effects in patients with early breast cancer a randomized clinical trial. JAMA On- col. 2016; 2: 1030-1037. 31. Guglin M, Krischer J, Tamura R et al. Rando- mized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019; 73: 2859-2868. 32. Huang S, Zhao Q, Yang ZG et al. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity: a systematic review and meta- analysis of carvedilol. Heart Fail Rev. 2019; 24: 325-333. 33. Vaduganathan M, Hirji SA, Qamar A et al. Effi- cacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer under- going chemotherapy. JACC CardioOncology. 2019; 1: 54-65. 34. Li X, Li Y, Zhang T, Xiong X et al. Role of car-